1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Liver Diseases - Pipeline Review, H2 2013

Liver Diseases - Pipeline Review, H2 2013

  • October 2013
  • -
  • Global Markets Direct
  • -
  • 91 pages

Liver Diseases - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Liver Diseases - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Liver Diseases, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Liver Diseases. Liver Diseases - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Liver Diseases.
- A review of the Liver Diseases products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Liver Diseases pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Liver Diseases.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Liver Diseases pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Liver Diseases - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Liver Diseases Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Liver Diseases 10
Liver Diseases Therapeutics under Development by Companies 12
Liver Diseases Therapeutics under Investigation by Universities/Institutes 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Liver Diseases Therapeutics - Products under Development by Companies 18
Liver Diseases Therapeutics - Products under Investigation by Universities/Institutes 19
Companies Involved in Liver Diseases Therapeutics Development 20
Isis Pharmaceuticals, Inc. 20
Hadasit Medical Research Services and Development Ltd 21
International Stem Cell Corporation 22
Arrowhead Research Corporation 23
PAION AG 24
Alnylam Pharmaceuticals, Inc 25
Proteonomix, Inc. 26
StemCells, Inc. 27
VistaGen Therapeutics , Inc. 28
Jenrin Discovery, Inc. 29
Hutchison MediPharma Limited 30
Ventria Bioscience 31
TetraLogic Pharmaceuticals 32
IC-MedTech, Inc. 33
Jenken Biosciences, Inc 34
MAKScientific, LLC 35
FCB-Pharmicell Co.,Ltd. 36
Liver Diseases - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Route of Administration 39
Assessment by Molecule Type 41
Drug Profiles 43
HMPL-011 - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
ulimorelin hydrochloride - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
Human Liver Engrafting Cells - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
Necrostatin Program - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
JD-2000 Series - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
JD-5000 Series - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
JD-6000 Series - Drug Profile 52
Product Description 52
Mechanism of Action 52
RandD Progress 52
remimazolam - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
JKB-121 - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
JKB-119 - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
HYPER-IL-6 - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
UMK-121 - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
ISIS-AATRx - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
Cell Therapy For Liver Repair - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
NKT II Cell Modulator - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
ALN-AAT - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
PV-905 - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
Livercellgram - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
Human Parthenogenetic Stem Cell Derived Hepatocytes - Drug Profile 65
Product Description 65
Mechanism of Action 65
RandD Progress 65
Compounds For Lung And Liver Disease - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
RXI-209 - Drug Profile 68
Product Description 68
Mechanism of Action 68
RandD Progress 68
JD-5006 - Drug Profile 69
Product Description 69
Mechanism of Action 69
RandD Progress 69
JD-5037 - Drug Profile 70
Product Description 70
Mechanism of Action 70
RandD Progress 70
AM-6545 - Drug Profile 71
Product Description 71
Mechanism of Action 71
RandD Progress 71
FFP-104 - Drug Profile 73
Product Description 73
Mechanism of Action 73
RandD Progress 73
RNA Interference For Liver Diseases - Drug Profile 74
Product Description 74
Mechanism of Action 74
RandD Progress 74
Liver Diseases Therapeutics - Drug Profile Updates 75
Liver Diseases Therapeutics - Discontinued Products 83
Liver Diseases Therapeutics - Dormant Products 84
Liver Diseases - Product Development Milestones 85
Featured News and Press Releases 85
Sep 23, 2013: Galectin Therapeutics Leadership to Present at Three Upcoming Conferences 85
Sep 05, 2013: Cempra's Solithromycin Demonstrates Safety and Tolerability in Patients With Chronic Liver Disease 85
May 02, 2013: Arena Pharma Withdraws European Marketing Authorization Application For Belviq 86
Mar 06, 2013: Silence Reports Results From Proof-of-concept Studies In Acute Liver Injury 86
Jan 08, 2013: Proteonomix Updates Status Of UMK-121 Testing 86
Nov 20, 2012: Proteonomix Announces Screening Of Patients With End Stage Liver Disease In Clinical Study Of UMK-121 87
Oct 26, 2012: Proteonomix Announces Finalizing ECRF For Clinical Trial Of UMK 121 In Patients With End Stage Liver Disease 87
Oct 12, 2012: StemCells Receives Broad US Patent Covering Expandable Liver Cells 87
Oct 04, 2012: Proteonomix Receives IRB Approval For Clinical Trial Of UMK-121 In Patients With End Stage Liver Disease 88
Sep 12, 2012: Proteonomix Retains Numoda To Provide Clinical Trial Services For Phase I Trial With UMK-121 In End-Stage Liver Disease 88
Appendix 90
Methodology 90
Coverage 90
Secondary Research 90
Primary Research 90
Expert Panel Validation 90
Contact Us 91
Disclaimer 91



List of Tables

Number of Products Under Development for Liver Diseases, H2 2013 10
Products under Development for Liver Diseases - Comparative Analysis, H2 2013 11
Number of Products under Development by Companies, H2 2013 13
Number of Products under Investigation by Universities/Institutes, H2 2013 14
Comparative Analysis by Mid Clinical Stage Development, H2 2013 15
Comparative Analysis by Early Clinical Stage Development, H2 2013 16
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 17
Products under Development by Companies, H2 2013 18
Products under Investigation by Universities/Institutes, H2 2013 19
Isis Pharmaceuticals, Inc., H2 2013 20
Hadasit Medical Research Services and Development Ltd, H2 2013 21
International Stem Cell Corporation, H2 2013 22
Arrowhead Research Corporation, H2 2013 23
PAION AG, H2 2013 24
Alnylam Pharmaceuticals, Inc, H2 2013 25
Proteonomix, Inc., H2 2013 26
StemCells, Inc., H2 2013 27
VistaGen Therapeutics , Inc., H2 2013 28
Jenrin Discovery, Inc., H2 2013 29
Hutchison MediPharma Limited, H2 2013 30
Ventria Bioscience, H2 2013 31
TetraLogic Pharmaceuticals, H2 2013 32
IC-MedTech, Inc., H2 2013 33
Jenken Biosciences, Inc, H2 2013 34
MAKScientific, LLC, H2 2013 35
FCB-Pharmicell Co.,Ltd., H2 2013 36
Assessment by Monotherapy Products, H2 2013 37
Assessment by Combination Products, H2 2013 38
Assessment by Stage and Route of Administration, H2 2013 40
Assessment by Stage and Molecule Type, H2 2013 42
Liver Diseases Therapeutics - Drug Profile Updates 75
Liver Diseases Therapeutics - Discontinued Products 83
Liver Diseases Therapeutics - Dormant Products 84



List of Figures

Number of Products under Development for Liver Diseases, H2 2013 10
Products under Development for Liver Diseases - Comparative Analysis, H2 2013 11
Products under Development by Companies, H2 2013 12
Products under Investigation by Universities/Institutes, H2 2013 14
Mid Clinical Stage Products, H2 2013 15
Early Clinical Stage Products, H2 2013 16
Discovery and Pre-Clinical Stage Products, H2 2013 17
Assessment by Monotherapy Products, H2 2013 37
Assessment by Combination Products, H2 2013 38
Assessment by Route of Administration, H2 2013 39
Assessment by Stage and Route of Administration, H2 2013 40
Assessment by Molecule Type, H2 2013 41
Assessment by Stage and Molecule Type, H2 2013 42



Companies Mentioned

Isis Pharmaceuticals, Inc.
Hadasit Medical Research Services and Development Ltd
International Stem Cell Corporation
Arrowhead Research Corporation
PAION AG
Alnylam Pharmaceuticals, Inc
Proteonomix, Inc.
StemCells, Inc.
VistaGen Therapeutics , Inc.
Jenrin Discovery, Inc.
Hutchison MediPharma Limited
Ventria Bioscience
TetraLogic Pharmaceuticals
IC-MedTech, Inc.
Jenken Biosciences, Inc
MAKScientific, LLC
FCB-Pharmicell Co.,Ltd.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016 Summary Global Markets ...

Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Pipeline Review, H2 2016

Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Pipeline ...

Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Pipeline Review, H2 2016

Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Caspase 7 (Apoptotic Protease Mch 3 or ICE Like Apoptotic Protease 3 or CMH 1 or CASP7 or EC 3.4.22.60) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Caspase 7 (Apoptotic Protease Mch ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.